EUVIMEDEUVIMED entdecken
Crossref

CpG-Adjuvanted Heplisav-B Induces Strong Th1-Biased Innate Responses Compared to Alum-Adjuvanted HBV Vaccines in PLWH 2308661

Jenny Lee, Prasanthy Balasubramanian, Yufeng Liu, Zachary Bakewell, Nirvani Jairam, Samuel Warner, Weiqiang Zhou, Andrew Karaba, Justin Bailey, Eileen Scully, Andrea Cox

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.1455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Jenny Lee und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alum-adjuvanted HBV vaccines such as Engerix-B offer limited protection for people living with HIV (PLWH), achieving only 35—70% seroprotection (as defined by HBsAb titers ≥10 mIU/mL). While Heplisav-B’s CpG 1018 adjuvant improves immunogenicity in PLWH, its mechanisms for overcoming HIV-related immune dysfunction are not yet defined.

Methods

We performed multiplex cytokine/chemokine profiling assays and high-dimensional flow cytometry, including markers to interrogate cellular metabolism, to characterize early innate responses 24 hours after the first dose of Engerix-B or Heplisav-B in PLWH who were non-responders to prior HBV vaccination.

Results

Heplisav-B induced robust early innate activation, characterized by significantly elevated IP-10, MCP-2, and IFN-γ versus baseline, consistent with Th1-skewed inflammatory profile that was not observed following Engerix-B vaccination. Heplisav-B produced an increased frequency of B cells following vaccination, but the cellular immunometabolic expression profiles were otherwise not significantly different between the two vaccines 24 hours after vaccination. This suggests that global immune cell proportions were largely maintained despite differences in cytokine induction. However, 24-hour cytokine levels predictive of seroprotection were distinct between vaccines, with low IL-17A production following Heplisav-B and low IL-2 and IL-4 production following Engerix-B being the strongest predictors of antibody responses.

Conclusion

Heplisav-B induces stronger Th1-skewed innate responses and increased B cell frequency than Engerix-B in PLWH within the first 24 hours of vaccination, while overall cellular composition and activation remain largely preserved. These findings provide mechanistic insight into how TLR9-targeting adjuvants can enhance vaccine immunogenicity in immunocompromised populations and suggest that response to the two vaccines may be driven through different innate immune pathways. Funding Source NIH/NIAID R01AI186730 Topic Categories Vaccines and Immunotherapy (VAC)

Zitieren

APA

Lee, J., Balasubramanian, P., Liu, Y., Bakewell, Z., Jairam, N., Warner, S., Zhou, W., Karaba, A., Bailey, J., Scully, E., & Cox, A. (2026). CpG-Adjuvanted Heplisav-B Induces Strong Th1-Biased Innate Responses Compared to Alum-Adjuvanted HBV Vaccines in PLWH 2308661. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1455

Vancouver

Lee J, Balasubramanian P, Liu Y, Bakewell Z, Jairam N, Warner S, et al. CpG-Adjuvanted Heplisav-B Induces Strong Th1-Biased Innate Responses Compared to Alum-Adjuvanted HBV Vaccines in PLWH 2308661. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1455

BibTeX
@article{Lee2026,
  author = {Lee, Jenny and Balasubramanian, Prasanthy and Liu, Yufeng and Bakewell, Zachary and Jairam, Nirvani and Warner, Samuel and Zhou, Weiqiang and Karaba, Andrew and Bailey, Justin and Scully, Eileen and Cox, Andrea},
  title = {CpG-Adjuvanted Heplisav-B Induces Strong Th1-Biased Innate Responses Compared to Alum-Adjuvanted HBV Vaccines in PLWH 2308661},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.1455}
}
Kostenlos starten →